The use of animal models that recapitulate the critical features of the disease, such as NFTs, cognitive impairment, brain atrophy, and neuronal loss, greatly facilitates the evaluations of tau‐targeting therapies. The gene discussed is MAPT; the disease is Brain atrophy.